Organon Financial Statements (OGN)
|
|
|
|
Report date
|
|
|
21.03.2022 |
27.02.2023 |
26.02.2024 |
28.02.2025 |
24.02.2026 |
|
04.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
6 304 |
6 174 |
6 263 |
6 403 |
6 216 |
|
6 163 |
|
Operating Income, bln rub |
|
|
1 915 |
1 705 |
1 327 |
1 486 |
1 285 |
|
1 185 |
|
EBITDA, bln rub |
? |
|
1 982 |
1 756 |
1 436 |
1 604 |
1 282 |
|
1 325 |
|
Net profit, bln rub |
? |
|
1 351 |
917.0 |
1 023 |
864.0 |
187.0 |
|
246.0 |
|
|
OCF, bln rub |
? |
|
2 458 |
858.0 |
799.0 |
939.0 |
700.0 |
|
850.0 |
|
CAPEX, bln rub |
? |
|
488.0 |
427.0 |
261.0 |
351.0 |
162.0 |
|
236.0 |
|
FCF, bln rub |
? |
|
1 970 |
431.0 |
538.0 |
588.0 |
538.0 |
|
614.0 |
|
Dividend payout, bln rub
|
|
|
145.0 |
290.0 |
294.0 |
297.0 |
88.0 |
|
22.0 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
10.7% |
31.6% |
28.7% |
34.4% |
47.1% |
|
8.94% |
|
|
OPEX, bln rub |
|
|
2 007 |
2 175 |
2 421 |
2 229 |
2 087 |
|
2 088 |
|
Cost of production, bln rub |
|
|
2 382 |
2 294 |
2 515 |
2 688 |
2 854 |
|
2 890 |
|
R&D, bln rub |
|
|
443.0 |
471.0 |
528.0 |
469.0 |
366.0 |
|
363.0 |
|
Interest expenses, bln rub |
|
|
258.0 |
422.0 |
527.0 |
520.0 |
504.0 |
|
492.0 |
|
|
Assets, bln rub |
|
|
10 681 |
10 955 |
12 058 |
13 101 |
12 867 |
|
12 996 |
|
Net Assets, bln rub |
? |
|
-1 508 |
-892.0 |
-70.0 |
472.0 |
752.0 |
|
903.0 |
|
Debt, bln rub |
|
|
9 364 |
9 112 |
8 931 |
9 036 |
8 800 |
|
8 569 |
|
Cash, bln rub |
|
|
737.0 |
706.0 |
693.0 |
675.0 |
574.0 |
|
1 116 |
|
Net debt, bln rub |
|
|
8 627 |
8 406 |
8 238 |
8 361 |
8 226 |
|
7 453 |
|
|
Ordinary share price, rub |
|
|
30.5 |
27.9 |
14.4 |
14.9 |
7.17 |
|
13.3 |
|
Number of ordinary shares, mln |
|
|
253.6 |
254.1 |
255.2 |
257.0 |
259.5 |
|
260.4 |
|
|
Market cap, bln rub |
|
|
7 721 |
7 097 |
3 681 |
3 835 |
1 861 |
|
3 473 |
|
EV, bln rub |
? |
|
16 348 |
15 503 |
11 919 |
12 196 |
10 087 |
|
10 926 |
|
Book value, bln rub |
|
|
-6 762 |
-6 144 |
-5 206 |
-5 622 |
-4 531 |
|
-4 349 |
|
|
EPS, rub |
? |
|
5.33 |
3.61 |
4.01 |
3.36 |
0.72 |
|
0.94 |
|
FCF/share, rub |
|
|
7.77 |
1.70 |
2.11 |
2.29 |
2.07 |
|
2.36 |
|
BV/share, rub |
|
|
-26.7 |
-24.2 |
-20.4 |
-21.9 |
-17.5 |
|
-16.7 |
|
|
EBITDA margin, % |
? |
|
31.4% |
28.4% |
22.9% |
25.1% |
20.6% |
|
21.5% |
|
Net margin, % |
? |
|
21.4% |
14.9% |
16.3% |
13.5% |
3.01% |
|
3.99% |
|
FCF yield, % |
? |
|
25.5% |
6.07% |
14.6% |
15.3% |
28.9% |
|
17.7% |
|
ROE, % |
? |
|
-89.6% |
-102.8% |
-1 461% |
183.1% |
24.9% |
|
27.2% |
|
ROA, % |
? |
|
12.6% |
8.37% |
8.48% |
6.59% |
1.45% |
|
1.89% |
|
|
P/E |
? |
|
5.71 |
7.74 |
3.60 |
4.44 |
9.95 |
|
14.1 |
|
P/FCF |
|
|
3.92 |
16.5 |
6.84 |
6.52 |
3.46 |
|
5.66 |
|
P/S |
? |
|
1.22 |
1.15 |
0.59 |
0.60 |
0.30 |
|
0.56 |
|
P/BV |
? |
|
-1.14 |
-1.16 |
-0.71 |
-0.68 |
-0.41 |
|
-0.80 |
|
EV/EBITDA |
? |
|
8.25 |
8.83 |
8.30 |
7.60 |
7.87 |
|
8.25 |
|
Debt/EBITDA |
|
|
4.35 |
4.79 |
5.74 |
5.21 |
6.41 |
|
5.62 |
|
|
R&D/CAPEX, % |
|
|
90.8% |
110.3% |
202.3% |
133.6% |
225.9% |
|
153.8% |
|
|
CAPEX/Revenue, % |
|
|
7.74% |
6.92% |
4.17% |
5.48% |
2.61% |
|
3.83% |
|
| Organon shareholders |
